In 2017 Dechra delivered 20 years of growth through our strategic growth drivers Portfolio Focus, Pipeline Delivery, Geographic Expansion and Acquisition.
Our total revenue of £359.3m in 2017 represents a 45.1% growth on the previous year (at Actual Exchange rate) and 28.3% growth (at Constant Exchange Rate).
Our key areas of expertise span endocrinology, dermatology, cardiology, water soluble powder products and injectable antibiotics, anaesthetics and analgesics, equine medicine and diet and nutrition. Our major products include:
Navigation